Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

XANA

Financiado

Innovative Wearable and Open Platform for a Personalized Treatment of Stress

The XANA project aims at developing a user-friendly wearable device and ICT solution for the customized treatment of stress. We will provide an innovative and non-invasive technology of stimulation of the vagus nerve and a range o... ver más

30/11/2017

WALDEN MEDICAL NEU...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

WALDEN MEDICAL NEURO DIGITAL THERAPIES Cnae 7211 si alguna de las siguientes actividades tuviera caracter profesional la sociedad actuara como mediadora. a-el diseño, desarrollo y...

TRL 3-4 | 333K€

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-11-30

SMEInst-01-2016-2017: Open Disruptive Innovation Scheme

I+D

Cerrada hace 8 años

0% 70% 100%

1 Participantes

WALDEN MEDICAL NEURO DIGITAL...

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 4 meses Fecha Inicio: 2017-07-17
Fecha Fin: 2017-11-30

Líder del proyecto

WALDEN MEDICAL NEURO DIGITAL THERAPIES Cnae 7211 si alguna de las siguientes actividades tuviera caracter profesional la sociedad actuara como mediadora. a-el diseño, desarrollo y...

TRL 3-4 | 333K€

Presupuesto del proyecto 71K€

Descripción del proyecto The XANA project aims at developing a user-friendly wearable device and ICT solution for the customized treatment of stress. We will provide an innovative and non-invasive technology of stimulation of the vagus nerve and a range of integrated services such as feedback on performance, monitoring and access to professional counselling when needed. Stress is suffered by over 26% of working population. The European Commission estimated in 2002 the cost of work-related stress at €20 billion a year just in the EU-15. Of this, direct costs are mostly paid by the public healthcare systems, and indirect costs are related to productivity loss, ultimately impacting national economies. Current alternatives do not fully solve the challenge of stress treatment, because of their limited efficacy and presence of secondary effects (invasive electrical stimulation or pharmacological treatment). Moreover, the treatment results are very variable, time consuming (psychological techniques) and expensive. XANA main benefits are: avoidance of secondary effects, high efficacy, user-friendliness, fast and customized treatment providing actual physiological activity. XANA will contribute to the development of mobile Health in Europe. In this, the ICT characteristics of the product are key to possibly enabling burden-reduction in healthcare systems through real-time treatment optimisation and remote medical monitoring/counselling. XANA project is led by the Spanish start-up Walden Medical®. XANA has a clear potential for becoming an international benchmark in the field of mental health. We have estimated that after 5 years from launch, we will build around 69.700 devices (sales €28M), hire 12 technical employees and manage 0.1% of the world market. We will earn around €10M profit and generate a R.O.I of 6.90. Investment in the XANA product will furthermore ease commercialization of Walden Medical® technologies for other high prevalence conditions: anxiety and migraine.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores